Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Imugene ( (AU:IMU) ).
Imugene Ltd and JW Therapeutics have announced a strategic collaboration to evaluate a novel combination therapy using Imugene’s onCARlytics oncolytic virus and JW’s CD19 CAR-T cell therapy, Carteyva®, targeting refractory solid tumors. This collaboration will involve preclinical studies and a Phase 1 trial in China, leveraging a ‘mark and kill’ strategy to make solid tumors targetable by CD19-CAR T cells. The initiative aims to generate impactful data efficiently and explore a breakthrough treatment paradigm for solid tumors, ensuring disciplined capital allocation and strategic flexibility.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene is a clinical-stage immuno-oncology company focused on developing novel immunotherapies designed to activate the immune system to treat and eradicate tumors. Their platform technologies aim to harness the body’s immune system against tumors, potentially achieving effects similar to or greater than those of synthetically manufactured monoclonal antibodies and other immunotherapies. The company’s pipeline includes an off-the-shelf cell therapy CAR T drug targeting CD19 for blood cancers and oncolytic virotherapy aimed at treating various cancers in combination with standard care drugs and emerging immunotherapies.
Average Trading Volume: 2,331,149
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$99.33M
For an in-depth examination of IMU stock, go to TipRanks’ Overview page.